Levofloxacin Hikma

Levofloxacin, the active ingredient in Levofloxacin Hikma, is a fluoroquinolone presented as an injectable solution for intravenous use. It treats a broad range of bacterial infections in adult and pediatric patients where an IV formulation is appropriate, and is indicated for severe infections requiring systemic therapy under medical supervision.

GNH USA supplies Levofloxacin Hikma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide, providing reliable sourcing, regulatory support and logistics for global healthcare providers.

Levofloxacin is a broad‑spectrum fluoroquinolone antibacterial that acts on bacterial DNA replication pathways.

Community‑acquired pneumonia: reduces bacterial load and shortens recovery time in patients with typical and atypical pathogens. Acute bacterial sinusitis: alleviates infection symptoms by eradicating susceptible organisms in the sinus mucosa. Urinary tract infection: clears uropathogenic bacteria, providing symptomatic relief and preventing complications. Skin and skin‑structure infections: treats complicated cellulitis and wound infections caused by Gram‑negative and Gram‑positive bacteria. Complicated intra‑abdominal infection: provides coverage against mixed aerobic and anaerobic organisms in severe abdominal sepsis.

Levofloxacin may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild gastrointestinal upset occurring in many patients. - Diarrhea: loose stools that are usually self‑limiting. - Headache: transient cranial discomfort. - Dizziness: occasional light‑headedness. - Insomnia: difficulty falling or staying asleep. - Rash: mild skin erythema or pruritus.

Serious or Rare Side Effects: - Tendon rupture: sudden tendon pain or rupture, especially in the Achilles tendon. - QT interval prolongation: cardiac rhythm disturbances that may lead to arrhythmia. - Clostridioides difficile infection: severe colitis following disruption of gut flora. - Severe allergic reaction: anaphylaxis, angioedema, or Stevens‑Johnson syndrome. - Hepatic dysfunction: elevated liver enzymes or jaundice. - Seizures: central nervous system excitation in susceptible individuals.

Before initiating levofloxacin therapy, clinicians should consider several precautionary measures to minimise risk. - Assess renal function: dose adjustment may be required in patients with impaired clearance. - Monitor for tendon pain: discontinue if sudden pain or inflammation occurs. - Avoid in patients with known hypersensitivity: discontinue at first sign of allergic reaction. - Use cautiously in QT‑prolonging conditions: obtain baseline ECG in high‑risk individuals. - Adjust dose in elderly: consider reduced dosing due to altered pharmacokinetics. - Store at room temperature: keep in original packaging, protect from moisture and light.

Levofloxacin can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Antacids containing magnesium or aluminum: chelate the drug and markedly reduce absorption. - Warfarin: may increase INR and bleeding risk. - Theophylline: levofloxacin can raise plasma theophylline levels, risking toxicity. - Cyclosporine: increased cyclosporine concentrations may occur. - NSAIDs (e.g., ibuprofen): heightened risk of central nervous system stimulation and seizures.

Moderate Interactions (Monitor Closely): - Corticosteroids: combined use raises risk of tendon rupture. - Diabetic agents (e.g., insulin, sulfonylureas): may cause hypoglycaemia. - Other QT‑prolonging drugs (e.g., macrolides, antiarrhythmics): additive effect on cardiac repolarisation. - Oral contraceptives: possible reduction in efficacy, advise backup contraception.